Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2021 | Eptinezumab initiated during a migraine prolongs time to subsequent attacks

Roger Cady, MD, Lundbeck Pharmaceutical, shares the results of secondary analyses conducted as part of the RELIEF trial, assessing the safety and efficacy of eptinezumab initiated during a migraine attack. Primary results from the RELIEF trial demonstrated that eptinezumab treatment led to significantly faster headache pain freedom and absence of most bothersome symptom (MBS) compared to placebo. Time to next migraine was assessed as an exploratory endpoint and it was shown that eptinezumab given during a migraine attack increased the time to next migraine, with a median of ten days compared to five days for placebo. Another analysis looked at the Migraine Treatment Optimization Questionnaire (mTOQ) to assess response to acute treatment. Dr Cady highlights that two domains, return to function and two hour pain freedom, were significantly improved for migraine attacks that occurred after the attack treated in the study. Finally, Dr Cady discusses an exploratory analysis of time to symptom resolution, which showed that epitenzumab separated from placebo by one hour for photophobia, phonophobia and nausea. This interview took place during the European Academy of Neurology 2021 congress.